| Item Type | Name |
|
Concept
|
Proto-Oncogene Proteins
|
|
Concept
|
Proto-Oncogene Proteins pp60(c-src)
|
|
Concept
|
Oncogene Proteins
|
|
Concept
|
Proto-Oncogene Proteins c-fos
|
|
Concept
|
Proto-Oncogene Proteins c-myc
|
|
Concept
|
Proto-Oncogene Proteins c-raf
|
|
Concept
|
Proto-Oncogene Proteins c-kit
|
|
Concept
|
Proto-Oncogene Proteins c-jun
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Concept
|
Oncogene Proteins v-fos
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Academic Article
|
Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line.
|
|
Academic Article
|
Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene.
|
|
Academic Article
|
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
|
|
Academic Article
|
Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
|
|
Academic Article
|
Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades.
|
|
Academic Article
|
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.
|
|
Academic Article
|
Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation.
|
|
Academic Article
|
PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
|
|
Academic Article
|
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
|
|
Academic Article
|
Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
|
|
Academic Article
|
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
|
|
Academic Article
|
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.
|
|
Academic Article
|
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
|
|
Academic Article
|
Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis.
|
|
Academic Article
|
Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
|
|
Academic Article
|
A special key for unlocking the door to targeted therapies of breast cancer.
|
|
Academic Article
|
Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras.
|
|
Academic Article
|
Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.
|
|
Academic Article
|
Tyrosine kinase mutations in human cancer.
|
|
Academic Article
|
Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences.
|
|
Academic Article
|
Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
|
|
Academic Article
|
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.
|
|
Academic Article
|
Epithelial ovarian cancer experimental models.
|
|
Academic Article
|
WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
|
|
Academic Article
|
Whole-genome characterization of chemoresistant ovarian cancer.
|
|
Academic Article
|
The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
|
|
Academic Article
|
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.
|
|
Academic Article
|
MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment.
|
|
Academic Article
|
Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.
|
|
Academic Article
|
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
|
|
Academic Article
|
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.
|